Innate Pharma SA
Close on Oct 19, 2026
About Innate Pharma
Biological Products, (No Diagnostic Substances), SIC 2836
Innate Pharma S.A. is a clinical-stage biotechnology company that develops immunotherapies for cancer patients. The company utilizes antibody-engineering expertise to create next-generation antibody therapeutics, focusing on oncology indications with high unmet medical needs. Its clinical drug pipeline includes lacutamab, an antibody targeting KIR3DL2 for T-cell lymphomas; IPH4502, an antibody-drug conjugate directed against Nectin-4 for solid tumors; and monalizumab, an immune checkpoint inhibitor targeting NKG2A. Innate collaborates with major biopharmaceutical companies, such as AstraZeneca and Sanofi, as well as academic and research institutions, which act as development partners and commercial collaborators.
The company maintains its corporate headquarters in Marseille, France, along with a wholly owned subsidiary located in Rockville, Maryland, in the United States. Innate operates research and development facilities across both France and the United States. In addition, its multi-center clinical trials involve clinical sites situated throughout the United States and Europe, including trial locations in France, Italy, Spain, Germany, Belgium, Poland, and Austria.
Summary of the business section of Innate Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Innate Pharma SA
- Founded
- 1999
- Headquarters
- Marseille, France
- Address
- 117 Avenue De Luminy, Bp 30191 13009
- Phone
- 33430303030
- Website
- innate-pharma.com
- Employees
- 181, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Associes, Le Bouscat
Stock & identifiers
- Ticker
- IPHA
- Other tickers
- IPHYF
- Exchange
- Nasdaq
- IPO date
- Oct 18, 2019
- Shares outstanding
- 94M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1598599
- CUSIP
- 45781K204
- ISIN
- US45781K2042
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Innate Pharma's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“As of December 31, 2024, the Company had 181 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 18, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 10, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |